Literature DB >> 30250891

Targeting kinases with precision.

Alexandra K Gardino1, Erica K Evans1, Joseph L Kim1, Natasja Brooijmans1, Brian L Hodous2, Beni Wolf1, Christoph Lengauer1,3.   

Abstract

Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in a variety of activation mechanisms. The challenge has been to match these insights with tailored drug discovery strategies to yield potent, highly selective drugs. With optimized drugs in hand, physicians could apply the principles of personalized medicine with an increasing number of options to treat patients with improved precision according to their tumor's molecular genotype.

Entities:  

Keywords:  BLU-285; avapritinib; gastrointestinal stromal tumor; precision medicine; systemic mastocytosis

Year:  2018        PMID： 30250891      PMCID： PMC6149809          DOI： 10.1080/23723556.2018.1435183

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  8 in total

Review 1.  The GIST paradigm: lessons for other kinase-driven cancers.

Authors:  Cristina R Antonescu
Journal:  J Pathol       Date:  2010-10-26       Impact factor: 7.996

2.  A precision therapy against cancers driven by KIT/PDGFRA mutations.

Authors:  Erica K Evans; Alexandra K Gardino; Joseph L Kim; Brian L Hodous; Adam Shutes; Alison Davis; Xing Julia Zhu; Oleg Schmidt-Kittler; Doug Wilson; Kevin Wilson; Lucian DiPietro; Yulian Zhang; Natasja Brooijmans; Timothy P LaBranche; Agnieszka Wozniak; Yemarshet K Gebreyohannes; Patrick Schöffski; Michael C Heinrich; Daniel J DeAngelo; Stephen Miller; Beni Wolf; Nancy Kohl; Timothy Guzi; Nicholas Lydon; Andy Boral; Christoph Lengauer
Journal:  Sci Transl Med       Date:  2017-11-01       Impact factor: 17.956

3.  Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.

Authors:  Philippe A Cassier; Elena Fumagalli; Piotr Rutkowski; Patrick Schöffski; Martine Van Glabbeke; Maria Debiec-Rychter; Jean-François Emile; Florence Duffaud; Javier Martin-Broto; Bruno Landi; Antoine Adenis; François Bertucci; Emmanuelle Bompas; Olivier Bouché; Serge Leyvraz; Ian Judson; Jaap Verweij; Paolo Casali; Jean-Yves Blay; Peter Hohenberger
Journal:  Clin Cancer Res       Date:  2012-06-20       Impact factor: 12.531

4.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

Authors:  Andres C Garcia-Montero; Maria Jara-Acevedo; Cristina Teodosio; Maria Luz Sanchez; Rosa Nunez; Aranzazu Prados; Isabel Aldanondo; Laura Sanchez; Mercedes Dominguez; Luis M Botana; Francisca Sanchez-Jimenez; Karl Sotlar; Julia Almeida; Luis Escribano; Alberto Orfao
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

5.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

6.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

7.  AACR Project GENIE: Powering Precision Medicine through an International Consortium.

Authors: 
Journal:  Cancer Discov       Date:  2017-06-01       Impact factor: 39.397

8.  KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Authors:  Ketan S Gajiwala; Joe C Wu; James Christensen; Gayatri D Deshmukh; Wade Diehl; Jonathan P DiNitto; Jessie M English; Michael J Greig; You-Ai He; Suzanne L Jacques; Elizabeth A Lunney; Michele McTigue; David Molina; Terri Quenzer; Peter A Wells; Xiu Yu; Yan Zhang; Aihua Zou; Mark R Emmett; Alan G Marshall; Hui-Min Zhang; George D Demetri
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-21       Impact factor: 11.205
  8 in total
  2 in total

1.  KinCon: Cell-based recording of full-length kinase conformations.

Authors:  Florian Enzler; Philipp Tschaikner; Rainer Schneider; Eduard Stefan
Journal:  IUBMB Life       Date:  2020-02-06       Impact factor: 3.885

2.  Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.

Authors:  Angélica Sandoval-Pérez; Beth Apsel Winger; Matthew P Jacobson
Journal:  J Chem Theory Comput       Date:  2022-09-27       Impact factor: 6.578
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.